SCoV-2 Ag Detect™ Rapid Test
FDA Emergency Use Authorized and CE Marked

The SCoV-2 Ag Detect™ Rapid Test is a lateral flow chromatographic immunoassay intended for the qualitative detection of the SARS-CoV-2 nucleocapsid protein antigen in direct anterior nasal swab specimens from individuals who are suspected of COVID-19 by their healthcare provider.

Resources
The SCoV-2 Ag Detect™ Rapid Test is a lateral flow chromatographic immunoassay intended for the qualitative detection of the SARS-CoV-2 nucleocapsid protein antigen in direct anterior nasal swab specimens from individuals who are suspected of COVID-19 by their healthcare provider within the first 5 days of symptom onset when tested at least twice over three days with at least 48 hours between tests and from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested at least three times over five days with at least 48 hours between tests. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The SCoV-2 Ag Detect™ Rapid Test does not differentiate between SARS-CoV and SARS-CoV-2.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen, which is generally detectable in anterior nasal (nares) swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.
All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be considered in the context of an individual’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.
The SCoV-2 Ag Detect™ Rapid Test is intended for use by medical professionals or operators who are proficient in performing tests in point of care settings. The SCoV-2 Ag Detect™ Rapid Test is only for in vitro diagnostic use under the Food and Drug Administration’s Emergency Use Authorization. This product has not been FDA cleared or approved.
• This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories;
• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and,
• The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Point of Care: Can be performed in a variety of settings, from physician offices to school health clinics, with symptomatic or asymptomatic individuals
Identifies acute infection in symptomatic patients:
-
- PPA (Relative Sensitivity): 86.67%
- NPA (Relative Specificity): 100%
-
Uses direct nasal samples without transport media
Includes everything required to perform test – no instrumentation needed
Includes 50 tests, swabs for sample collection, and positive and negative controls
Simple to use and requires minimal training
Room temperature storage
Fast results in ~20 minutes
100% manufactured in the USA
SCoV-2 Ag Detect™ Rapid Test is patent pending
Initial studies suggest this test will detect the Delta variant at rates similar to the USA-WA1-2020 isolate that was used to develop the assay.
Catalog No. | COVAG-RC | COVAG-20 |
Format | ICT (cassette) | ICT (cassette) |
Quantity/Kit | 50 | 20 |
Time to Result | ~20 minutes | ~20 minutes |
Sample Type | Direct nasal swabs | Direct nasal swabs |
Storage | Room Temperature (15°C-30°C) | Room Temperature (15°C-30°C) |
Shelf Life | 13 months | 13 months |
For more information, download the Instructions For Use via the “Downloads” tab.